José Ramón Santos

Summary

Affiliation: Lluita contra la SIDA Foundation
Country: Spain

Publications

  1. pmc Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    PLoS ONE 8:e70201. 2013
  2. pmc Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    PLoS ONE 7:e37442. 2012
  3. doi request reprint Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    J Antimicrob Chemother 67:1462-9. 2012
  4. doi request reprint Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 27:713-7. 2011
  5. doi request reprint Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice
    José Ramón Santos
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    HIV Clin Trials 10:129-34. 2009
  6. doi request reprint Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    HIV Clin Trials 10:432-8. 2009
  7. doi request reprint Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    AIDS Res Hum Retroviruses 26:1191-6. 2010
  8. doi request reprint Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients
    Jose Molto
    Lluita contra Sida Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 15:219-25. 2010
  9. ncbi request reprint Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Clin Pharmacokinet 47:681-92. 2008
  10. ncbi request reprint Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice
    Jose Molto
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, and Universidad Autonoma de Barcelona, Spain
    J Antimicrob Chemother 60:436-9. 2007

Detail Information

Publications16

  1. pmc Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    PLoS ONE 8:e70201. 2013
    ..Data on suppression of HIV replication in the CNS and on the subsequent risk of neurocognitive impairment using monotherapy with boosted protease inhibitors are limited...
  2. pmc Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    PLoS ONE 7:e37442. 2012
    ....
  3. doi request reprint Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    J Antimicrob Chemother 67:1462-9. 2012
    ..To assess the most frequent resistance-associated mutations (RAMs) to lopinavir/ritonavir in a cohort of patients attended in daily practice...
  4. doi request reprint Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 27:713-7. 2011
    ....
  5. doi request reprint Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice
    José Ramón Santos
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    HIV Clin Trials 10:129-34. 2009
    ....
  6. doi request reprint Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    HIV Clin Trials 10:432-8. 2009
    ..To assess the Efficacy and safety of switching from HAART containing enfuvirtide to raltegravir as a simplification strategy in patients with viral suppression and intolerance to enfuvirtide...
  7. doi request reprint Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    AIDS Res Hum Retroviruses 26:1191-6. 2010
    ....
  8. doi request reprint Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients
    Jose Molto
    Lluita contra Sida Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 15:219-25. 2010
    ..We explored a treatment simplification strategy to darunavir/ritonavir 900/100 mg once daily guided by the darunavir virtual inhibitory quotient (vIQ) in patients receiving salvage therapy with darunavir/ritonavir 600/100 mg twice daily...
  9. ncbi request reprint Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Clin Pharmacokinet 47:681-92. 2008
    ..It is coformulated with low doses of ritonavir in order to enhance its pharmacokinetic profile. After oral administration, plasma concentrations of lopinavir can vary widely between different HIV-infected patients...
  10. ncbi request reprint Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice
    Jose Molto
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, and Universidad Autonoma de Barcelona, Spain
    J Antimicrob Chemother 60:436-9. 2007
    ..The objective of this study was to assess the effectiveness and safety of monotherapy with lopinavir/ritonavir as a treatment simplification strategy in HIV-infected patients with viral suppression outside a clinical trial setting...
  11. doi request reprint Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications
    Eugenia Negredo
    Lluita contra Sida Foundation, Institut de Recerca en Ciències de Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Infect Dis 50:1300-8. 2010
    ..Although antiretroviral therapy improves immune response, some human immunodeficiency virus-infected patients present unsatisfactory CD4 T cell recovery despite achieving viral suppression, resulting in increased morbidity and mortality...
  12. doi request reprint Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Antimicrob Chemother 62:784-92. 2008
    ....
  13. ncbi request reprint Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Ther Drug Monit 29:648-51. 2007
    ..Therapeutic drug monitoring may be useful in this setting...
  14. doi request reprint [Etravirine: genetic barrier and resistance development]
    Josep M Llibre
    Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Espana
    Enferm Infecc Microbiol Clin 27:32-9. 2009
    ..4) in up to 1 out of every 3 samples analyzed. The early withdrawal of first-generation NNRTIs in patients with virological failure is essential to avoid the accumulation of mutations that could compromise the activity of this drug...
  15. doi request reprint Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure
    Francisco M Codoñer
    HIVACAT, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antiviral Res 88:281-6. 2010
    ....
  16. doi request reprint A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors
    Maria José Buzón
    Institut de Recerca de SIDA IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    J Antimicrob Chemother 67:32-8. 2012
    ..We describe the molecular mechanism of a non-infectious HIV-1 protease phenotypic assay in eukaryotic cells and validate its applicability as a tool for monitoring drug resistance...